|Classification and external resources|
|ICD-9-CM||274.00 274.1 274.8 274.9|
|eMedicine||emerg/221 med/924 med/1112 oph/506 orthoped/124 radio/313|
Gout (also known as podagra when it involves the big toe) is a medical condition usually characterized by recurrent attacks of acute inflammatory arthritis—a red, tender, hot, swollen joint. The metatarsal-phalangeal joint at the base of the big toe is the most commonly affected (approximately 50% of cases). It may also present as tophi, kidney stones, or urate nephropathy. It is caused by elevated levels of uric acid in the blood. The uric acid crystallizes, and the crystals deposit in joints, tendons, and surrounding tissues.
Clinical diagnosis may be confirmed by seeing the characteristic crystals in joint fluid. Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, or colchicine improves symptoms. Once the acute attack subsides, levels of uric acid are usually lowered via lifestyle changes, and in those with frequent attacks, allopurinol or probenecid provides long-term prevention.
Gout has become more common in recent decades, affecting about 1 to 2% of the Western population at some point in their lives. The increase is believed to be due to increasing risk factors in the population, such as metabolic syndrome, longer life expectancy, and changes in diet. Gout was historically known as "the disease of kings" or "rich man's disease."
- 1 Signs and symptoms
- 2 Cause
- 3 Pathophysiology
- 4 Diagnosis
- 5 Prevention
- 6 Treatment
- 7 Prognosis
- 8 Epidemiology
- 9 History
- 10 Other animals
- 11 Research
- 12 References
- 13 External links
Signs and symptoms
Gout can present in a number of ways, although the most usual is a recurrent attack of acute inflammatory arthritis (a red, tender, hot, swollen joint). The metatarsal-phalangeal joint at the base of the big toe is affected most often, accounting for half of cases. Other joints, such as the heels, knees, wrists, and fingers, may also be affected. Joint pain usually begins over 2–4 hours and during the night. The reason for onset at night is due to the lower body temperature then. Other symptoms may rarely occur along with the joint pain, including fatigue and a high fever.
Long-standing elevated uric acid levels (hyperuricemia) may result in other symptomatology, including hard, painless deposits of uric acid crystals known as tophi. Extensive tophi may lead to chronic arthritis due to bone erosion. Elevated levels of uric acid may also lead to crystals precipitating in the kidneys, resulting in stone formation and subsequent urate nephropathy.
The crystallization of uric acid, often related to relatively high levels in the blood, is the underlying cause of gout. This can occur for a number of reasons, including diet, genetic predisposition, or underexcretion of urate, the salts of uric acid. Underexcretion of uric acid by the kidney is the primary cause of hyperuricemia in about 90% of cases, while overproduction is the cause in less than 10%. About 10% of people with hyperuricemia develop gout at some point in their lifetimes. The risk, however, varies depending on the degree of hyperuricemia. When levels are between 415 and 530 μmol/l (7 and 8.9 mg/dl), the risk is 0.5% per year, while in those with a level greater than 535 μmol/l (9 mg/dL), the risk is 4.5% per year.
Dietary causes account for about 12% of gout, and include a strong association with the consumption of alcohol, fructose-sweetened drinks, meat, and seafood. Other triggers include physical trauma and surgery.
Studies in the early 2000s have found that other dietary factors once believed associated are, in fact, not. Specifically, moderate consumption of purine-rich vegetables (e.g. beans, peas, lentils, and spinach) are not associated with the development of gout. Neither is total consumption of protein. With respect to risks related to alcohol, beer and spirits appear to have a greater risk than wine.
The consumption of coffee, vitamin C, and dairy products, as well as physical fitness, appear to decrease the risk. This is believed partly due to their effect in reducing insulin resistance.
The occurrence of gout is partly genetic, contributing to about 60% of variability in uric acid level. Three genes called SLC2A9, SLC22A12, and ABCG2 have been found commonly associated with gout, and variations in them can approximately double the risk. Loss-of-function mutations in SLC2A9 and SLC22A12 cause hereditary hypouricaemia by reducing urate absorption and unopposed urate secretion. A few rare genetic disorders, including familial juvenile hyperuricemic nephropathy, medullary cystic kidney disease, phosphoribosylpyrophosphate synthetase superactivity, and hypoxanthine-guanine phosphoribosyltransferase deficiency as seen in Lesch-Nyhan syndrome, are complicated by gout.
Gout frequently occurs in combination with other medical problems. Metabolic syndrome, a combination of abdominal obesity, hypertension, insulin resistance, and abnormal lipid levels, occurs in nearly 75% of cases. Other conditions commonly complicated by gout include: polycythemia, lead poisoning, renal failure, hemolytic anemia, psoriasis, and solid organ transplants. A body mass index greater than or equal to 35 increases a male's risk of gout threefold. Chronic lead exposure and lead-contaminated alcohol are risk factors for gout due to the harmful effect of lead on kidney function. Lesch-Nyhan syndrome is often associated with gouty arthritis.
Diuretics have been associated with attacks of gout. However, a low dose of hydrochlorothiazide does not seem to increase the risk. Other medicines that increase the risk include niacin and aspirin (acetylsalicylic acid). The immunosuppressive drugs ciclosporin and tacrolimus are also associated with gout, the former more so when used in combination with hydrochlorothiazide.
Gout is a disorder of purine metabolism, and occurs when its final metabolite, uric acid, crystallizes in the form of monosodium urate, precipitating and forming deposits (tophi) in joints, on tendons, and in the surrounding tissues. Microscopic tophi may be walled off by a ring of proteins, which blocks interaction of the crystals with cells, and therefore avoids inflammation. Naked crystals may break out of walled-off tophi due to minor physical trauma to the joint, medical or surgical stress, or rapid changes in uric acid levels. When they breach the tophi, they trigger a local immune-mediated inflammatory reaction, with one of the key proteins in the inflammatory cascade being interleukin 1β. An evolutionary loss of urate oxidase (uricase), which breaks down uric acid, in humans and higher primates has made this condition common.
The triggers for precipitation of uric acid are not well understood. While it may crystallize at normal levels, it is more likely to do so as levels increase. Other factors believed important in triggering an acute episode of arthritis include cool temperatures, rapid changes in uric acid levels, acidosis, articular hydration, and extracellular matrix proteins, such as proteoglycans, collagens, and chondroitin sulfate. The increased precipitation at low temperatures partly explains why the joints in the feet are most commonly affected. Rapid changes in uric acid may occur due to a number of factors, including trauma, surgery, chemotherapy, diuretics, and stopping or starting allopurinol. Calcium channel blockers and losartan are associated with a lower risk of gout compared to other medications for hypertension.
Gout may be diagnosed and treated without further investigations in someone with hyperuricemia and the classic podagra. Synovial fluid analysis should be done, however, if the diagnosis is in doubt. X-rays, while useful for identifying chronic gout, have little utility in acute attacks.
A definitive diagnosis of gout is based upon the identification of monosodium urate crystals in synovial fluid or a tophus. All synovial fluid samples obtained from undiagnosed inflamed joints should be examined for these crystals. Under polarized light microscopy, they have a needle-like morphology and strong negative birefringence. This test is difficult to perform, and often requires a trained observer. The fluid must also be examined relatively quickly after aspiration, as temperature and pH affect their solubility.
Hyperuricemia is a classic feature of gout, but it occurs nearly half of the time without hyperuricemia, and most people with raised uric acid levels never develop gout. Thus, the diagnostic utility of measuring uric acid level is limited. Hyperuricemia is defined as a plasma urate level greater than 420 μmol/l (7.0 mg/dl) in males and 360 μmol/l (6.0 mg/dl) in females. Other blood tests commonly performed are white blood cell count, electrolytes, renal function, and erythrocyte sedimentation rate (ESR). However, both the white blood cells and ESR may be elevated due to gout in the absence of infection. A white blood cell count as high as 40.0×109/l (40,000/mm3) has been documented.
The most important differential diagnosis in gout is septic arthritis. This should be considered in those with signs of infection or those who do not improve with treatment. To help with diagnosis, a synovial fluid Gram stain and culture may be performed. Other conditions that look similar include pseudogout and rheumatoid arthritis. Gouty tophi, in particular when not located in a joint, can be mistaken for basal cell carcinoma, or other neoplasms.
Both lifestyle changes and medications can decrease uric acid levels. Dietary and lifestyle choices that are effective include reducing intake of food such as meat and seafood, consuming adequate vitamin C, limiting alcohol and fructose consumption, and avoiding obesity. A low-calorie diet in obese men decreased uric acid levels by 100 µmol/l (1.7 mg/dl). Vitamin C intake of 1,500 mg per day decreases the risk of gout by 45%. Coffee, but not tea, consumption is associated with a lower risk of gout. Gout may be secondary to sleep apnea via the release of purines from oxygen-starved cells. Treatment of apnea can lessen the occurrence of attacks.
The initial aim of treatment is to settle the symptoms of an acute attack. Repeated attacks can be prevented by different drugs used to reduce the serum uric acid levels. Tentative evidence support the application of ice for 20 to 30 minutes several times a day to decrease pain. Options for acute treatment include nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and steroids, while options for prevention include allopurinol, febuxostat, and probenecid. Lowering uric acid levels can cure the disease. Treatment of associated health problems is also important. Lifestyle interventions have been poorly studied. It is unclear if dietary supplements have an effect in people with gout.
NSAIDs are the usual first-line treatment for gout, and no specific agent is significantly more or less effective than any other. Improvement may be seen within four hours, and treatment is recommended for one to two weeks. They are not recommended, however, in those with certain other health problems, such as gastrointestinal bleeding, renal failure, or heart failure. While indomethacin has historically been the most commonly used NSAID, an alternative, such as ibuprofen, may be preferred due to its better side effect profile in the absence of superior effectiveness. For those at risk of gastric side effects from NSAIDs, an additional proton pump inhibitor may be given. There is some evidence that COX-2 inhibitors may work as well as nonselective NSAIDs for acute gout attack with fewer side effects.
Colchicine is an alternative for those unable to tolerate NSAIDs. At high doses, side effects (primarily gastrointestinal upset) limit its usage. At lower doses, which are still effective, it is well tolerated. Colchicine may interact with other commonly prescribed drugs, such as atorvastatin and erythromycin, among others.
Glucocorticoids have been found as effective as NSAIDs and may be used if contraindications exist for NSAIDs. They also lead to improvement when injected into the joint; a joint infection must be excluded, however, as steroids worsens this condition.
Pegloticase was approved in the USA to treat gout in 2010. It is an option for the 3% of people who are intolerant to other medications. Pegloticase is administered as an intravenous infusion every two weeks, and has been found to reduce uric acid levels in this population. It is likely useful for tophi but has a high rate of side effects.
A number of medications are useful for preventing further episodes of gout, including xanthine oxidase inhibitor (including allopurinol and febuxostat) and uricosurics (including probenecid and sulfinpyrazone). They are not usually started until one to two weeks after an acute flare has resolved, due to theoretical concerns of worsening the attack, and are often used in combination with either an NSAID or colchicine for the first three to six months. They are not recommended until a person has had two attacks of gout, unless destructive joint changes, tophi, or urate nephropathy exist, as medications have not been found cost-effective until this point. Urate-lowering measures should be increased until serum uric acid levels are below 300–360 µmol/l (5.0–6.0 mg/dl), and are continued indefinitely. If these medications are being used chronically at the time of an attack, discontinuation is recommended. If levels cannot be brought below 6.0 mg/dl and there are recurrent attacks, this is deemed treatment failure or refractory gout. Overall, probenecid appears less effective than allopurinol.
Uricosuric medications are typically preferred if undersecretion of uric acid, as indicated by a 24-hour collection of urine results in a uric acid amount of less than 800 mg, is found. They are, however, not recommended if a person has a history of kidney stones. In a 24-hour urine excretion of more than 800 mg, which indicates overproduction, a xanthine oxidase inhibitor is preferred.
Xanthine oxidase inhibitors (including allopurinol and febuxostat) block uric acid production, and long-term therapy is safe and well tolerated, and can be used in people with renal impairment or urate stones, although allopurinol has caused hypersensitivity in a small number of individuals. In such cases, the alternative drug, febuxostat, has been recommended.
Without treatment, an acute attack of gout usually resolves in five to seven days; however, 60% of people have a second attack within one year. Those with gout are at increased risk of hypertension, diabetes mellitus, metabolic syndrome, and renal and cardiovascular disease, and thus are at increased risk of death. This may be partly due to its association with insulin resistance and obesity, but some of the increased risk appears to be independent.
Without treatment, episodes of acute gout may develop into chronic gout with destruction of joint surfaces, joint deformity, and painless tophi. These tophi occur in 30% of those who are untreated for five years, often in the helix of the ear, over the olecranon processes, or on the Achilles tendons. With aggressive treatment, they may dissolve. Kidney stones also frequently complicate gout, affecting between 10 and 40% of people, and occur due to low urine pH promoting the precipitation of uric acid. Other forms of chronic renal dysfunction may occur.
Nodules of the finger and helix of the ear representing gouty tophi
Gout affects around 1–2% of the Western population at some point in their lifetimes, and is becoming more common. Rates of gout have approximately doubled between 1990 and 2010. This rise is believed due to increasing life expectancy, changes in diet, and an increase in diseases associated with gout, such as metabolic syndrome and high blood pressure. A number of factors have been found to influence rates of gout, including age, race, and the season of the year. In men over the age of 30 and women over the age of 50, prevalence is 2%.
In the United States, gout is twice as likely in African American males as it is in European Americans. Rates are high among the peoples of the Pacific Islands and the Māori of New Zealand, but rare in Australian aborigines, despite a higher mean concentration of serum uric acid in the latter group. It has become common in China, Polynesia, and urban sub-Saharan Africa. Some studies have found attacks of gout occur more frequently in the spring. This has been attributed to seasonal changes in diet, alcohol consumption, physical activity, and temperature.
The word "gout" was initially used by Randolphus of Bocking, around 1200 AD. It is derived from the Latin word gutta, meaning "a drop" (of liquid). According to the Oxford English Dictionary, this is derived from humorism and "the notion of the 'dropping' of a morbid material from the blood in and around the joints".
Gout has, however, been known since antiquity. Historically, it has been referred to as "the king of diseases and the disease of kings" or "rich man's disease". The first documentation of the disease is from Egypt in 2,600 BC in a description of arthritis of the big toe. The Greek physician Hippocrates around 400 BC commented on it in his Aphorisms, noting its absence in eunuchs and premenopausal women. Aulus Cornelius Celsus (30 AD) described the linkage with alcohol, later onset in women, and associated kidney problems:
Again thick urine, the sediment from which is white, indicates that pain and disease are to be apprehended in the region of joints or viscera... Joint troubles in the hands and feet are very frequent and persistent, such as occur in cases of podagra and cheiragra. These seldom attack eunuchs or boys before coition with a woman, or women except those in whom the menses have become suppressed... some have obtained lifelong security by refraining from wine, mead and venery.
In 1683, Thomas Sydenham, an English physician, described its occurrence in the early hours of the morning, and its predilection for older males:
Gouty patients are, generally, either old men, or men who have so worn themselves out in youth as to have brought on a premature old age—of such dissolute habits none being more common than the premature and excessive indulgence in venery, and the like exhausting passions. The victim goes to bed and sleeps in good health. About two o'clock in the morning he is awakened by a severe pain in the great toe; more rarely in the heel, ankle or instep. The pain is like that of a dislocation, and yet parts feel as if cold water were poured over them. Then follows chills and shivers, and a little fever... The night is passed in torture, sleeplessness, turning the part affected, and perpetual change of posture; the tossing about of body being as incessant as the pain of the tortured joint, and being worse as the fit comes on.
The Dutch scientist Antonie van Leeuwenhoek first described the microscopic appearance of urate crystals in 1679. In 1848, English physician Alfred Baring Garrod realized this excess uric acid in the blood was the cause of gout.
Gout is rare in most other animals due to their ability to produce uricase, which breaks down uric acid. Humans and other great apes do not have this ability, thus gout is common. Other animals with uricase include fish, amphibians, and most non primate mammals. The Tyrannosaurus rex specimen known as "Sue", however, is believed to have suffered from gout.
A number of new medications are under study for treating gout, including anakinra, canakinumab, and rilonacept. Canakinumab may result in better outcomes than a low dose of a steroid but costs five thousand times more. A recombinant uricase enzyme (rasburicase) is available; its use, however, is limited, as it triggers an autoimmune response. Less antigenic versions are in development.
- Brookhiser, Richard (2008). Gentleman Revolutionary: Gouverneur Morris, the Rake Who Wrote the Constitution. Simon and Schuster. p. 212. ISBN 9781439104088.
- Haslam, Fiona (1996). From Hogarth to Rowlandson : medicine in art in eighteenth-century Britain (1. publ. ed.). Liverpool: Liverpool University Press. p. 143. ISBN 9780853236405.
- Eggebeen AT (2007). "Gout: an update". Am Fam Physician 76 (6): 801–8. PMID 17910294.
- Chen LX, Schumacher HR (October 2008). "Gout: an evidence-based review". J Clin Rheumatol 14 (5 Suppl): S55–62. doi:10.1097/RHU.0b013e3181896921. PMID 18830092.
- Schlesinger N (March 2010). "Diagnosing and treating gout: a review to aid primary care physicians". Postgrad Med 122 (2): 157–61. doi:10.3810/pgm.2010.03.2133. PMID 20203467.
- Terkeltaub R (January 2010). "Update on gout: new therapeutic strategies and options". Nature Reviews Rheumatology 6 (1): 30–8. doi:10.1038/nrrheum.2009.236. PMID 20046204.
- Tausche AK, Jansen TL, Schröder HE, Bornstein SR, Aringer M, Müller-Ladner U (August 2009). "Gout—current diagnosis and treatment". Dtsch Arztebl Int 106 (34–35): 549–55. doi:10.3238/arztebl.2009.0549. PMC 2754667. PMID 19795010.
- Richette P, Bardin T (January 2010). "Gout". Lancet 375 (9711): 318–28. doi:10.1016/S0140-6736(09)60883-7. PMID 19692116.
- Vitart V, Rudan I, Hayward C et al. (April 2008). "SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout". Nat. Genet. 40 (4): 437–42. doi:10.1038/ng.106. PMID 18327257.
- Weaver, AL (July 2008). "Epidemiology of gout". Cleveland Clinic journal of medicine. 75 Suppl 5: S9–12. doi:10.3949/ccjm.75.Suppl_5.S9. PMID 18819329.
- Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (March 2004). "Purine-rich foods, dairy and protein intake, and the risk of gout in men". N. Engl. J. Med. 350 (11): 1093–103. doi:10.1056/NEJMoa035700. PMID 15014182.
- Weaver AL (2008). "Epidemiology of gout". Cleve Clin J Med. 75 Suppl 5: S9–12. doi:10.3949/ccjm.75.Suppl_5.S9. PMID 18819329.
- Singh, JA; Reddy, SG; Kundukulam, J (March 2011). "Risk factors for gout and prevention: a systematic review of the literature.". Current opinion in rheumatology 23 (2): 192–202. doi:10.1097/BOR.0b013e3283438e13. PMID 21285714.
- Roddy, Edward (Oct 1, 2013). "Gout". BMJ 347. doi:10.1136/bmj.f5648.
- Hak AE, Choi HK (March 2008). "Lifestyle and gout". Curr Opin Rheumatol 20 (2): 179–86. doi:10.1097/BOR.0b013e3282f524a2. PMID 18349748.
- Williams PT (May 2008). "Effects of diet, physical activity and performance, and body weight on incident gout in ostensibly healthy, vigorously active men". Am. J. Clin. Nutr. 87 (5): 1480–7. PMID 18469274.
- Choi HK (March 2010). "A prescription for lifestyle change in patients with hyperuricemia and gout". Curr Opin Rheumatol 22 (2): 165–72. doi:10.1097/BOR.0b013e328335ef38. PMID 20035225.
- Merriman, TR; Dalbeth, N (2011). "The genetic basis of hyperuricaemia and gout.". Joint, bone, spine : revue du rhumatisme 78 (1): 35–40. doi:10.1016/j.jbspin.2010.02.027. PMID 20472486.
- Reginato AM, Mount DB, Yang I, Choi HK (2012). "The genetics of hyperuricaemia and gout". Nature Reviews Rheumatology 8 (10): 610–21. doi:10.1038/nrrheum.2012.144. PMC 3645862. PMID 22945592.
- Stamp L, Searle M, O'Donnell J, Chapman P (2005). "Gout in solid organ transplantation: a challenging clinical problem". Drugs 65 (18): 2593–611. doi:10.2165/00003495-200565180-00004. PMID 16392875.
- Loghman-Adham M (September 1997). "Renal effects of environmental and occupational lead exposure". Environ. Health Perspect. (Brogan & Partners) 105 (9): 928–38. doi:10.2307/3433873. JSTOR 3433873. PMC 1470371. PMID 9300927.
- Laubscher T, Dumont Z, Regier L, Jensen B (December 2009). "Taking the stress out of managing gout". Can Fam Physician 55 (12): 1209–12. PMC 2793228. PMID 20008601.
- Firestein, MD, Gary S.; Budd, MD, Ralph C.; Harris Jr., MD, Edward D.; McInnes PhD, FRCP, Iain B.; Ruddy, MD, Shaun; Sergent, MD, John S., eds. (2008). "Chapter 87: Gout and Hyperuricemia". Kelley's Textbook of Rheumatology (8th ed.). Elsevier. ISBN 978-1-4160-4842-8.
- Liu-Bryan, Ru; Terkeltaub, Robert (2006). "Evil humors take their Toll as innate immunity makes gouty joints TREM-ble". Arthritis & Rheumatism 54 (2): 383–386. doi:10.1002/art.21634.
- Virsaladze DK, Tetradze LO, Dzhavashvili LV, Esaliia NG, Tananashvili DE (2007). "[Levels of uric acid in serum in patients with metabolic syndrome]" [Levels of uric acid in serum in patients with metabolic syndrome]. Georgian Med News (in Russian) (146): 35–7. PMID 17595458.
- Moyer RA, John DS (2003). "Acute gout precipitated by total parenteral nutrition". The Journal of rheumatology 30 (4): 849–50. PMID 12672211.
- Halabe A, Sperling O (1994). "Uric acid nephrolithiasis". Mineral and electrolyte metabolism 20 (6): 424–31. PMID 7783706.
- Choi HK, Soriano LC, Zhang Y, Rodríguez LA (2012). "Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study". BMJ 344: d8190. doi:10.1136/bmj.d8190. PMC 3257215. PMID 22240117.
- Schlesinger N (2007). "Diagnosis of gout". Minerva Med. 98 (6): 759–67. PMID 18299687.
- Sturrock R (2000). "Gout. Easy to misdiagnose". BMJ 320 (7228): 132–33. doi:10.1136/bmj.320.7228.132. PMC 1128728. PMID 10634714.
- Sachs L, Batra KL, Zimmermann B (2009). "Medical implications of hyperuricemia". Med Health R I 92 (11): 353–55. PMID 19999892.
- "Gout: Differential Diagnoses & Workup – eMedicine Rheumatology". Medscape.
- "Gout and Pseudogout: Differential Diagnoses & Workup – eMedicine Emergency Medicine". Medscape.
- Jordan DR, Belliveau MJ, Brownstein S, McEachren T, Kyrollos M (2008). "Medial canthal tophus". Ophthal Plast Reconstr Surg 24 (5): 403–4. doi:10.1097/IOP.0b013e3181837a31. PMID 18806664.
- Sano K, Kohakura Y, Kimura K, Ozeki S (March 2009). "Atypical Triggering at the Wrist due to Intratendinous Infiltration of Tophaceous Gout". Hand (N Y) 4 (1): 78–80. doi:10.1007/s11552-008-9120-4. PMC 2654956. PMID 18780009.
- Choi HK, Gao X, Curhan G (March 2009). "Vitamin C intake and the risk of gout in men: a prospective study". Arch. Intern. Med. 169 (5): 502–7. doi:10.1001/archinternmed.2008.606. PMC 2767211. PMID 19273781.
- Choi HK, Curhan G (June 2007). "Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey". Arthritis Rheum. 57 (5): 816–21. doi:10.1002/art.22762. PMID 17530681.
- Abrams B (2005). "Gout is an indicator of sleep apnea". Sleep 28 (2): 275. PMID 16171252.
- Zhang W, Doherty M, Bardin T et al. (October 2006). "EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)". Ann. Rheum. Dis. 65 (10): 1312–24. doi:10.1136/ard.2006.055269. PMC 1798308. PMID 16707532.
- Moi, JH; Sriranganathan, MK; Edwards, CJ; Buchbinder, R (4 November 2013). "Lifestyle interventions for acute gout.". The Cochrane database of systematic reviews 11: CD010519. doi:10.1002/14651858.CD010519.pub2. PMID 24186771.
- Moi, JH; Sriranganathan, MK; Edwards, CJ; Buchbinder, R (31 May 2013). "Lifestyle interventions for chronic gout.". The Cochrane database of systematic reviews 5: CD010039. doi:10.1002/14651858.CD010039.pub2. PMID 23728699.
- Andrés, M; Sivera, F; Falzon, L; Buchbinder, R; Carmona, L (Oct 7, 2014). "Dietary supplements for chronic gout.". The Cochrane database of systematic reviews 10: CD010156. doi:10.1002/14651858.CD010156.pub2. PMID 25287939.
- Winzenberg T, Buchbinder R (2009). "Cochrane Musculoskeletal Group review: acute gout. Steroids or NSAIDs? Let this overview from the Cochrane Group help you decide what's best for your patient". J Fam Pract 58 (7): E1–4. PMID 19607767.
- Clinical Knowledge Summaries. "Gout – Management – What treatment is recommended in acute gout?". U.K. National Library for Health. Retrieved 2008-10-26.
- van Durme, CM; Wechalekar, MD; Landewé, RB (9 June 2015). "Nonsteroidal anti-inflammatory drugs for treatment of acute gout.". JAMA 313 (22): 2276–7. PMID 26057289.
- van Durme, CM; Wechalekar, MD; Buchbinder, R; Schlesinger, N; van der Heijde, D; Landewé, RB (16 September 2014). "Non-steroidal anti-inflammatory drugs for acute gout.". The Cochrane database of systematic reviews 9: CD010120. PMID 25225849.
- "Information for Healthcare Professionals: New Safety Information for Colchicine (marketed as Colcrys)". U.S. Food and Drug Administration.
- van Echteld, I; Wechalekar, MD; Schlesinger, N; Buchbinder, R; Aletaha, D (Aug 15, 2014). "Colchicine for acute gout.". The Cochrane database of systematic reviews 8: CD006190. doi:10.1002/14651858.CD006190.pub2. PMID 25123076.
- Man CY, Cheung IT, Cameron PA, Rainer TH (2007). "Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial". Annals of Emergency Medicine 49 (5): 670–7. doi:10.1016/j.annemergmed.2006.11.014. PMID 17276548.
- van Durme, CM; Wechalekar, MD; Buchbinder, R; Schlesinger, N; van der Heijde, D; Landewé, RB (Sep 16, 2014). "Non-steroidal anti-inflammatory drugs for acute gout.". The Cochrane database of systematic reviews 9: CD010120. doi:10.1002/14651858.CD010120.pub2. PMID 25225849.
- "FDA approves new drug for gout". FDA. September 14, 2010.
- Sundy, JS; Baraf, HS, Yood, RA, Edwards, NL, Gutierrez-Urena, SR, Treadwell, EL, Vázquez-Mellado, J, White, WB, Lipsky, PE, Horowitz, Z, Huang, W, Maroli, AN, Waltrip RW, 2nd, Hamburger, SA, Becker, MA (Aug 17, 2011). "Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials". JAMA: the Journal of the American Medical Association 306 (7): 711–20. doi:10.1001/jama.2011.1169. PMID 21846852.
- Sriranganathan, MK; Vinik, O; Bombardier, C; Edwards, CJ (Oct 20, 2014). "Interventions for tophi in gout.". The Cochrane database of systematic reviews 10: CD010069. doi:10.1002/14651858.CD010069.pub2. PMID 25330136.
- Ali, S; Lally, EV (November 2009). "Treatment failure gout". Medicine and health, Rhode Island 92 (11): 369–71. PMID 19999896.
- Elizabeth D Agabegi; Agabegi, Steven S. (2008). Step-Up to Medicine (Step-Up Series). Hagerstwon, MD: Lippincott Williams & Wilkins. p. 251. ISBN 0-7817-7153-6.
- "Febuxostat for the management of hyperuricaemia in people with gout (TA164) Chapter 4. Consideration of the evidence". Guidance.nice.org.uk. Retrieved 2011-08-20.
- Kim SY, De Vera MA, Choi HK (2008). "Gout and mortality". Clin. Exp. Rheumatol. 26 (5 Suppl 51): S115–9. PMID 19026153.
- Rheumatology Therapeutics Medical Center. "What Are the Risk Factors for Gout?". Retrieved 2007-01-26.
- Roberts-Thomson RA, Roberts-Thomson PJ (May 1999). "Rheumatic disease and the Australian aborigine". Ann. Rheum. Dis. 58 (5): 266–70. doi:10.1136/ard.58.5.266. PMC 1752880. PMID 10225809.
- Fam AG (May 2000). "What is new about crystals other than monosodium urate?". Curr Opin Rheumatol 12 (3): 228–34. doi:10.1097/00002281-200005000-00013. PMID 10803754.
- Pillinger, MH; Rosenthal P; Abeles AM (2007). "Hyperuricemia and gout: new insights into pathogenesis and treatment". Bulletin of the NYU Hospital for Joint Diseases 65 (3): 215–221. PMID 17922673.
- "gout, n.1.". Oxford English Dictionary, Second edition, 1989. Retrieved 18 September 2011.
- "The Disease Of Kings - Forbes.com". Forbes.
- "Rich Man's Disease – definition of Rich Man's Disease in the Medical dictionary". Free Online Medical Dictionary, Thesaurus and Encyclopedia.
- "The Internet Classics Archive Aphorisms by Hippocrates". MIT. Retrieved July 27, 2010.
- A. Cornelius Celsus. "On Medicine". University of Chicago. Book IV.
- "Gout – The Affliction of Kings". h2g2. BBC. December 23, 2012.
- Storey GD (October 2001). "Alfred Baring Garrod (1819–1907)". Rheumatology (Oxford, England) 40 (10): 1189–90. doi:10.1093/rheumatology/40.10.1189. PMID 11600751.
- Agudelo CA, Wise CM (2001). "Gout: diagnosis, pathogenesis, and clinical manifestations". Curr Opin Rheumatol 13 (3): 234–9. doi:10.1097/00002281-200105000-00015. PMID 11333355.
- Choi, HK; Mount, DB; Reginato, AM; American College of, Physicians; American Physiological, Society (4 October 2005). "Pathogenesis of gout.". Annals of internal medicine 143 (7): 499–516. doi:10.7326/0003-4819-143-7-200510040-00009. PMID 16204163.
- Rothschild, BM; Tanke D; Carpenter K (1997). "Tyrannosaurs suffered from gout". Nature 387 (6631): 357. doi:10.1038/387357a0. PMID 9163417.
- Abeles, A. M. and Pillinger, M. H. (March 8, 2010). "New therapeutic options for gout here and on the horizon". Journal of Musculoskeletal Medicine.
- Sivera, F; Wechalekar, MD; Andrés, M; Buchbinder, R; Carmona, L (Sep 1, 2014). "Interleukin-1 inhibitors for acute gout.". The Cochrane database of systematic reviews 9: CD009993. doi:10.1002/14651858.CD009993.pub2. PMID 25177840.
|Wikimedia Commons has media related to Gout.|